Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.

ABSTRACT:

Background

Infection-associated hemolytic uremic syndrome (IA-HUS), most often due to infection with Shiga toxin-producing bacteria, mainly affects young children. It can be acutely life-threatening, as well as cause long-term kidney and neurological morbidity. Specific treatment with proven efficacy is lacking. Since activation of the alternative complement pathway occurs in HUS, the monoclonal C5 antibody eculizumab is often used off-label once complications, e.g., seizures, occur. Eculizumab is prohibitively expensive and carries risk of infection. Its utility in IA-HUS has not been systematically studied. This systematic review aims to present, summarize, and evaluate all currently available data regarding the effect of eculizumab administration on medium- to long-term outcomes

SUBMITTER: de Zwart PL 

PROVIDER: S-EPMC10943142 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature